TGFBI and invasive breast carcinoma: In addition, the expression of TGFBI was also a poor indicator for bladder urothelial carcinoma (BLCA, n=406), breast invasive carcinoma (BRCA, n=841), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC, n=302), and glioblastoma multiforme (GBM, n=153); and the expression of HYAL1 was a statistical protective marker for kidney renal papillary cell carcinoma (KIRP, n=287) and pheochromocytoma (n=148) (Figure 6C).